Abstract
Coronary heart disease (CHD) continues to be a leading cause of morbidity and mortality in the western world. Pharmacological management with dual-antiplatelet therapy consisting of aspirin and a P2Y12 inhibitor forms the cornerstone of management of patients with CHD or an acute coronary syndrome (ACS). However, it is the use of interventional procedures, such as angioplasty and stenting to treat endothelial dysfunction secondary to atherosclerotic plaque rupture, that has revolutionised the management of patients who present with CHD including ACS. This is the first article in a two-part series, and provides an overview of the pathophysiology of CHD and ACS, as well as the initial strategies used in their management including thrombolysis, plain old balloon angioplasty (POBA) and bare metal stents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
